Merck & Co., Inc. continued its business development push in oncology on 5 November with the announcement that it will pay $2.75bn in cash for VelosBio Inc., a privately held developer of antibody-drug conjugates and bispecific antibodies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), in a deal that is expected to close by the end of 2020.
Merck Pays $2.75bn To Access VelosBio’s ROR1-Targeting ADCs
Private Biotech Raised $137m In Venture Capital In July
Merck continues its cancer deal streak, purchasing a pipeline of antibody-drug conjugates and bispecific antibodies against receptor tyrosine kinase-like orphan receptor 1 (ROR1).
